You need to enable JavaScript to run this app.
Recon: FDA approves first interchangeable biosimilar for Lucentis eye drug; Amgen to acquire ChemoCentryx for $4 billion
Recon
Joanne S. Eglovitch
Global
ReconJoanne S. Eglovitch
GlobalReconJoanne S. EglovitchGlobal